WALTHAM, Mass. - Revvity (NYSE: RVTY), a provider of health science solutions and services, announced a regular quarterly dividend of $0.07 per share. The dividend is scheduled for payment on May 9, 2025, to shareholders who are on record as of April 18, 2025. According to InvestingPro data, the company has maintained dividend payments for 55 consecutive years, demonstrating a strong commitment to shareholder returns.
The company, which is known for its work in translational multi-omics technologies, biomarker identification, and diagnostic services, has reported a revenue of over $2.7 billion for the year 2023. Currently trading near its 52-week high of $129.50, Revvity maintains a robust gross profit margin of 55.37% and commands a market capitalization of $14.9 billion. With more than 11,000 employees, Revvity has a customer base that spans across pharmaceutical and biotech industries, diagnostic laboratories, academia, and government sectors globally.
As a member of the S&P 500 index, Revvity has established a significant presence in the healthcare sector, providing technologies and expertise that aim to streamline workflows from research and development to diagnosis and treatment.
This dividend declaration reflects the company’s ongoing financial performance and commitment to delivering value to its shareholders. Revvity’s operation spans more than 190 countries, indicating its expansive reach in the healthcare solutions market.
The information in this article is based on a press release statement from Revvity.
"In other recent news, Revvity Inc. reported robust third-quarter 2024 financial results, with adjusted revenues of $684 million and an increase in adjusted operating margins to 28.3%. The company’s earnings per share (EPS) exceeded expectations, leading to an upward revision of the full-year adjusted EPS forecast. Additionally, a new $1 billion share repurchase plan was announced.
In other developments, Bernstein SocGen Group analysts have downgraded Revvity’s stock rating from Outperform to Market Perform, setting a new price target of $130.00. This shift reflects the analysts’ belief that the stock may not offer the same growth potential as it did previously, with the downgrade suggesting that Revvity is now expected to perform in line with the general market.
Furthermore, Revvity secured a new $1.5 billion unsecured revolving credit facility, extending its financial flexibility until 2030. The agreement, involving major financial institutions such as Bank of America, JPMorgan Chase (NYSE:JPM) Bank, and Goldman Sachs Bank, replaces a previous credit agreement.
These are recent developments, providing insight into Revvity’s financial performance and future expectations as stated by analysts."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.